Abstract
Serum samples from 429 cancer patients, 82 unpaid blood donors, and 74 paid blood donors were tested for hepatitis C virus (HCV) markers in two commercially available enzyme immunoassays (EIAs). A total of 229 of 429 (53.4%) cancer patients were positive by the two EIAs. A total of 34 of 156 (21.8%) of the blood donors were positive by the EIAs, with a higher prevalence among paid blood donors (20/74; 27%) compared with that among the unpaid blood donors (14 of 82; 17%). EIA-positive sera were tested for confirmation of the results in an immunoblot assay (LiaTek) in which reactivities to four synthetic peptides representing the HCV core protein and two synthetic peptides representing nonstructural proteins 4 and 5 were measured. Of 243 first and/or second EIA-positive samples from cancer patients, 188 (77.2%) were confirmed to be positive in the synthetic peptide immunoblot. A total of 33 of 35 (94.3%) blood donor samples were confirmed to be positive. A great diversity in reactivity patterns was seen. However, all sera from the group of paid blood donors were exclusively reactive to core peptides 1 and 2. A subset of LiaTek assay-positive samples were tested by the four-antigen RIBA-2 assay. The sera from the paid blood donors were all nonreactive. A subset of the LiaTek-positive sera was analyzed for the presence of the HCV genome by reverse transcriptase-PCR. Eleven of the 20 serum samples with reactivity to LiaTek core peptides 1 and 2 only were HCV reverse transcriptase-PCR positive, as were the majority of the sera with other reactivity patterns by the LiaTek assay. The results confirm the very high prevalence of HCV infection in Egypt. Furthermore, the results indicate that there is circulating in Egypt, particularly in the group of blood donors paid for their donation, an HCV variant which elicits an immune response that is not detected by the RIBA-2 assay.
Full Text
The Full Text of this article is available as a PDF (266.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boom R., Sol C. J., Heijtink R., Wertheim-van Dillen P. M., van der Noordaa J. Rapid purification of hepatitis B virus DNA from serum. J Clin Microbiol. 1991 Sep;29(9):1804–1811. doi: 10.1128/jcm.29.9.1804-1811.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Boom R., Sol C. J., Salimans M. M., Jansen C. L., Wertheim-van Dillen P. M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990 Mar;28(3):495–503. doi: 10.1128/jcm.28.3.495-503.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
- Choo Q. L., Richman K. H., Han J. H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P. J. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451–2455. doi: 10.1073/pnas.88.6.2451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Choo Q. L., Weiner A. J., Overby L. R., Kuo G., Houghton M., Bradley D. W. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990 Apr;46(2):423–441. doi: 10.1093/oxfordjournals.bmb.a072408. [DOI] [PubMed] [Google Scholar]
- Darwish M. A., Raouf T. A., Rushdy P., Constantine N. T., Rao M. R., Edelman R. Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. Am J Trop Med Hyg. 1993 Oct;49(4):440–447. doi: 10.4269/ajtmh.1993.49.440. [DOI] [PubMed] [Google Scholar]
- Dawson G. J., Lesniewski R. R., Stewart J. L., Boardway K. M., Gutierrez R. A., Pendy L., Johnson R. G., Alcalde X., Rote K. V., Devare S. G. Detection of antibodies to hepatitis C virus in U.S. blood donors. J Clin Microbiol. 1991 Mar;29(3):551–556. doi: 10.1128/jcm.29.3.551-556.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dusheiko G., Schmilovitz-Weiss H., Brown D., McOmish F., Yap P. L., Sherlock S., McIntyre N., Simmonds P. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994 Jan;19(1):13–18. [PubMed] [Google Scholar]
- Hibbs R. G., Corwin A. L., Hassan N. F., Kamel M., Darwish M., Edelman R., Constantine N. T., Rao M. R., Khalifa A. S., Mokhtar S. The epidemiology of antibody to hepatitis C in Egypt. J Infect Dis. 1993 Sep;168(3):789–790. doi: 10.1093/infdis/168.3.789. [DOI] [PubMed] [Google Scholar]
- Janot C., Couroucé A. M., Maniez M. Antibodies to hepatitis C virus in French blood donors. Lancet. 1989 Sep 30;2(8666):796–797. doi: 10.1016/s0140-6736(89)90851-9. [DOI] [PubMed] [Google Scholar]
- Kamel M. A., Ghaffar Y. A., Wasef M. A., Wright M., Clark L. C., Miller F. D. High HCV prevalence in Egyptian blood donors. Lancet. 1992 Aug 15;340(8816):427–427. doi: 10.1016/0140-6736(92)91508-6. [DOI] [PubMed] [Google Scholar]
- Kühnl P., Seidl S., Stangel W., Beyer J., Sibrowski W., Flik J. Antibody to hepatitis C virus in German blood donors. Lancet. 1989 Aug 5;2(8658):324–324. doi: 10.1016/s0140-6736(89)90500-x. [DOI] [PubMed] [Google Scholar]
- McOmish F., Yap P. L., Dow B. C., Follett E. A., Seed C., Keller A. J., Cobain T. J., Krusius T., Kolho E., Naukkarinen R. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994 Apr;32(4):884–892. doi: 10.1128/jcm.32.4.884-892.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pawlotsky J. M., Tsakiris L., Roudot-Thoraval F., Pellet C., Stuyver L., Duval J., Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis. 1995 Jun;171(6):1607–1610. doi: 10.1093/infdis/171.6.1607. [DOI] [PubMed] [Google Scholar]
- Saeed A. A., al-Admawi A. M., al-Rasheed A., Fairclough D., Bacchus R., Ring C., Garson J. Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh. Lancet. 1991 Aug 17;338(8764):459–460. doi: 10.1016/0140-6736(91)91094-b. [DOI] [PubMed] [Google Scholar]
- Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., Watanabe Y., Koi S., Onji M., Ohta Y. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6547–6549. doi: 10.1073/pnas.87.17.6547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simmonds P., Holmes E. C., Cha T. A., Chan S. W., McOmish F., Irvine B., Beall E., Yap P. L., Kolberg J., Urdea M. S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993 Nov;74(Pt 11):2391–2399. doi: 10.1099/0022-1317-74-11-2391. [DOI] [PubMed] [Google Scholar]
- Simmonds P., McOmish F., Yap P. L., Chan S. W., Lin C. K., Dusheiko G., Saeed A. A., Holmes E. C. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol. 1993 Apr;74(Pt 4):661–668. doi: 10.1099/0022-1317-74-4-661. [DOI] [PubMed] [Google Scholar]
- Takano S., Omata M., Ohto M., Satomura Y. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis. Hepatology. 1993 Aug;18(2):235–239. [PubMed] [Google Scholar]
- van den Hoek J. A., van Haastrecht H. J., Goudsmit J., de Wolf F., Coutinho R. A. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis. 1990 Oct;162(4):823–826. doi: 10.1093/infdis/162.4.823. [DOI] [PubMed] [Google Scholar]